{"schemaVersion":"peptidescanner-evidence-bundle/v1","canonicalUrl":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json","manifestUrl":"https://peptidescanner.com/evidence/v1/manifest.json","peptide":{"slug":"trofinetide","name":"Trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"},"addressing":"objects is keyed by objectPathId. A URL fragment #<objectPathId> on this file names one evidence object. Every version of a record is placed in the bundle of the record's current first peptide.","objectCount":27,"objects":{"clinicaltrials-gov-nct02715115-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:clinicaltrials-gov-nct02715115-trofinetide:v1","objectPathId":"clinicaltrials-gov-nct02715115-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/clinicaltrials-gov-nct02715115-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#clinicaltrials-gov-nct02715115-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#clinicaltrials-gov-nct02715115-trofinetide-v1"},"story":{"slug":"clinicaltrials-gov-nct02715115-trofinetide","version":1,"domain":"Clinical trials","dateInSource":"2020-08-14","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"ClinicalTrials.gov record NCT02715115","sourceIds":["ctg-observation-nct02715115-2020-08-14-575a080ff61c"]},{"id":"summary","text":"PeptideScanner retained ClinicalTrials.gov record NCT02715115 at 2026-11-15T21:57:22.404Z. Its registry update date was 2020-08-14, and PeptideScanner's reviewed identity mapping was trofinetide.","sourceIds":["ctg-observation-nct02715115-2020-08-14-575a080ff61c"]},{"id":"paragraph-1","text":"PeptideScanner retained ClinicalTrials.gov record NCT02715115 at 2026-11-15T21:57:22.404Z. Its registry update date was 2020-08-14, and PeptideScanner's reviewed identity mapping was trofinetide.","sourceIds":["ctg-observation-nct02715115-2020-08-14-575a080ff61c"]},{"id":"paragraph-2","text":"This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective.","sourceIds":["ctg-observation-nct02715115-2020-08-14-575a080ff61c"]}],"sources":[{"id":"ctg-observation-nct02715115-2020-08-14-575a080ff61c","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT02715115 · retained source version 2020-08-14:575a080ff61c95fce5751935a4e62715a94fbceeef38ed21a742306ab03b8672","url":"https://clinicaltrials.gov/study/NCT02715115"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"213bfb72e2a20866605226e7b0e882560283c1c3143ba75541db4eb6fb23cd30","tierARecordSha256":"2989c1b3addc87316ebda6238542952d43b6b7f62ed7bff64a0fc914ce847a33"},"integrity":{"algorithm":"sha256","contentSha256":"4764a114315357fbf4b2ffb5b6ea7842fcf2af3c1dfa1ef904503e0fe843550e"}},"clinicaltrials-gov-nct04181723-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:clinicaltrials-gov-nct04181723-trofinetide:v1","objectPathId":"clinicaltrials-gov-nct04181723-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/clinicaltrials-gov-nct04181723-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#clinicaltrials-gov-nct04181723-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#clinicaltrials-gov-nct04181723-trofinetide-v1"},"story":{"slug":"clinicaltrials-gov-nct04181723-trofinetide","version":1,"domain":"Clinical trials","dateInSource":"2024-04-08","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"ClinicalTrials.gov record NCT04181723","sourceIds":["ctg-observation-nct04181723-2024-04-08-f2a2ceab7240"]},{"id":"summary","text":"PeptideScanner retained ClinicalTrials.gov record NCT04181723 at 2026-11-15T21:57:22.404Z. Its registry update date was 2024-04-08, and PeptideScanner's reviewed identity mapping was trofinetide.","sourceIds":["ctg-observation-nct04181723-2024-04-08-f2a2ceab7240"]},{"id":"paragraph-1","text":"PeptideScanner retained ClinicalTrials.gov record NCT04181723 at 2026-11-15T21:57:22.404Z. Its registry update date was 2024-04-08, and PeptideScanner's reviewed identity mapping was trofinetide.","sourceIds":["ctg-observation-nct04181723-2024-04-08-f2a2ceab7240"]},{"id":"paragraph-2","text":"This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective.","sourceIds":["ctg-observation-nct04181723-2024-04-08-f2a2ceab7240"]}],"sources":[{"id":"ctg-observation-nct04181723-2024-04-08-f2a2ceab7240","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT04181723 · retained source version 2024-04-08:f2a2ceab724054f77787c8658b99e54146297a04d8fa34d1473365c4ecc16dfd","url":"https://clinicaltrials.gov/study/NCT04181723"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"7f076e05754049d233eb9eeb17d4f9c9ebd9f5a0fd8eb0e38737e779adfcd67d","tierARecordSha256":"bc9edc4f226d879ce0452f0d75b79768c21cc092719a499a2c239ba3ac029bc1"},"integrity":{"algorithm":"sha256","contentSha256":"3eee8dda6358bb47fac172c5176e31c6dd5fd480b34c97d8ebde0aed1475742f"}},"clinicaltrials-gov-nct04279314-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:clinicaltrials-gov-nct04279314-trofinetide:v1","objectPathId":"clinicaltrials-gov-nct04279314-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/clinicaltrials-gov-nct04279314-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#clinicaltrials-gov-nct04279314-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#clinicaltrials-gov-nct04279314-trofinetide-v1"},"story":{"slug":"clinicaltrials-gov-nct04279314-trofinetide","version":1,"domain":"Clinical trials","dateInSource":"2024-04-11","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"ClinicalTrials.gov record NCT04279314","sourceIds":["ctg-observation-nct04279314-2024-04-11-0331ca281992"]},{"id":"summary","text":"PeptideScanner retained ClinicalTrials.gov record NCT04279314 at 2026-11-15T21:57:22.404Z. Its registry update date was 2024-04-11, and PeptideScanner's reviewed identity mapping was trofinetide.","sourceIds":["ctg-observation-nct04279314-2024-04-11-0331ca281992"]},{"id":"paragraph-1","text":"PeptideScanner retained ClinicalTrials.gov record NCT04279314 at 2026-11-15T21:57:22.404Z. Its registry update date was 2024-04-11, and PeptideScanner's reviewed identity mapping was trofinetide.","sourceIds":["ctg-observation-nct04279314-2024-04-11-0331ca281992"]},{"id":"paragraph-2","text":"This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective.","sourceIds":["ctg-observation-nct04279314-2024-04-11-0331ca281992"]}],"sources":[{"id":"ctg-observation-nct04279314-2024-04-11-0331ca281992","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT04279314 · retained source version 2024-04-11:0331ca2819920ba14b0889c926cedeef143b7e06b454764d87e6e8a15b2fc53e","url":"https://clinicaltrials.gov/study/NCT04279314"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"b9b5dea8139de47ba2e92256daa2d27d14ab4837c64744036f2dd43ccbf07739","tierARecordSha256":"d42fa26f0023e28e156af54c1961bba636aae1d7f77fbac5b6b1cd70fdf8c7b2"},"integrity":{"algorithm":"sha256","contentSha256":"d51eeb35c1997e592559463a74e6f14cfd0a47d797ee80b75d55a55321a54af7"}},"fda-drugs-nda217026-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:fda-drugs-nda217026:v1","objectPathId":"fda-drugs-nda217026-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/fda-drugs-nda217026/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#fda-drugs-nda217026-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#fda-drugs-nda217026-v1"},"story":{"slug":"fda-drugs-nda217026","version":1,"domain":"Regulatory","dateInSource":"2023-03-10","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Drugs@FDA application NDA217026","sourceIds":["fda-drugs-nda217026-2023-03-10-4bb0ba3bac8a"]},{"id":"summary","text":"The official Drugs@FDA dataset lists original submission 1 for NDA 217026 with status AP dated 2023-03-10, and names trofinetide among the application record's active ingredients.","sourceIds":["fda-drugs-nda217026-2023-03-10-4bb0ba3bac8a"]},{"id":"paragraph-1","text":"The official Drugs@FDA dataset lists original submission 1 for NDA 217026 with status AP dated 2023-03-10, and names trofinetide among the application record's active ingredients.","sourceIds":["fda-drugs-nda217026-2023-03-10-4bb0ba3bac8a"]},{"id":"paragraph-2","text":"This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance.","sourceIds":["fda-drugs-nda217026-2023-03-10-4bb0ba3bac8a"]}],"sources":[{"id":"fda-drugs-nda217026-2023-03-10-4bb0ba3bac8a","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application NDA217026 · original submission status AP · 2023-03-10 · dataset 2026-11-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA217026%22&limit=1"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"d7ce1376b5bddbe927bb14dc6b7c7f1594c6a85ba0d0d438a92d97b396ab252a","tierARecordSha256":"4bb0ba3bac8a8e4aa3e39da547399d8c11eb7711b4317812c7fc144cc61cbe27"},"integrity":{"algorithm":"sha256","contentSha256":"63e5c833f040625b2857928f63a3c2ac48576de8102ad634a35463e2850c46d1"}},"fda-drugs-nda219884-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:fda-drugs-nda219884:v1","objectPathId":"fda-drugs-nda219884-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/fda-drugs-nda219884/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#fda-drugs-nda219884-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#fda-drugs-nda219884-v1"},"story":{"slug":"fda-drugs-nda219884","version":1,"domain":"Regulatory","dateInSource":"2025-12-11","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Drugs@FDA application NDA219884","sourceIds":["fda-drugs-nda219884-2025-12-11-4f2f3a1ba50d"]},{"id":"summary","text":"The official Drugs@FDA dataset lists original submission 1 for NDA 219884 with status AP dated 2025-12-11, and names trofinetide among the application record's active ingredients.","sourceIds":["fda-drugs-nda219884-2025-12-11-4f2f3a1ba50d"]},{"id":"paragraph-1","text":"The official Drugs@FDA dataset lists original submission 1 for NDA 219884 with status AP dated 2025-12-11, and names trofinetide among the application record's active ingredients.","sourceIds":["fda-drugs-nda219884-2025-12-11-4f2f3a1ba50d"]},{"id":"paragraph-2","text":"This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance.","sourceIds":["fda-drugs-nda219884-2025-12-11-4f2f3a1ba50d"]}],"sources":[{"id":"fda-drugs-nda219884-2025-12-11-4f2f3a1ba50d","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application NDA219884 · original submission status AP · 2025-12-11 · dataset 2026-11-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA219884%22&limit=1"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"c5946b6fa52557cf51f7dc91f457b28c9209352b0eb2583f0a1019ff824bbbaf","tierARecordSha256":"4f2f3a1ba50d77a76861e49a8e212591a7b4fe40198b22c369f50bd121cb89d8"},"integrity":{"algorithm":"sha256","contentSha256":"909dc27392fa1c65e6f2e1e2aa32c29afc65adc0117b6d5c68f1f79eab6c8a22"}},"federal-register-2023-06593-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:federal-register-2023-06593:v1","objectPathId":"federal-register-2023-06593-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/federal-register-2023-06593/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#federal-register-2023-06593-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#federal-register-2023-06593-v1"},"story":{"slug":"federal-register-2023-06593","version":1,"domain":"Regulatory","dateInSource":"2023-03-30","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Federal Register notice 2023-06593","sourceIds":["federal-register-2023-06593-5a9a25299322"]},{"id":"summary","text":"The Federal Register published notice 2023-06593, attributed to FDA and its parent HHS department, on 2023-03-30. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product,” and PeptideScanner's exact reviewed identity mapping connects the document to Trofinetide.","sourceIds":["federal-register-2023-06593-5a9a25299322"]},{"id":"paragraph-1","text":"The Federal Register published notice 2023-06593, attributed to FDA and its parent HHS department, on 2023-03-30. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product,” and PeptideScanner's exact reviewed identity mapping connects the document to Trofinetide.","sourceIds":["federal-register-2023-06593-5a9a25299322"]},{"id":"paragraph-2","text":"This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use.","sourceIds":["federal-register-2023-06593-5a9a25299322"]}],"sources":[{"id":"federal-register-2023-06593-5a9a25299322","name":"Federal Register via GovInfo","sourceClass":"A","title":"Federal Register notice 2023-06593 · published 2023-03-30 · Issuance of Priority Review Voucher; Rare Pediatric Disease Product","url":"https://www.govinfo.gov/content/pkg/FR-2023-03-30/pdf/2023-06593.pdf"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"9699cd41e70fc6191ffa58957d1bdde5dd2c0761ec9893e67d16dfac640b5dd0","tierARecordSha256":"5a9a2529932238ad31aa9c0782cc25cb326d638a2829e91f013f8d747dcdef7b"},"integrity":{"algorithm":"sha256","contentSha256":"31a677c29f307bd2f5416fd5f58922a454b28436a058a7341e6085b690ccdeef"}},"federal-register-2024-21941-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:federal-register-2024-21941:v1","objectPathId":"federal-register-2024-21941-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/federal-register-2024-21941/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#federal-register-2024-21941-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#federal-register-2024-21941-v1"},"story":{"slug":"federal-register-2024-21941","version":1,"domain":"Regulatory","dateInSource":"2024-09-25","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Federal Register notice 2024-21941","sourceIds":["federal-register-2024-21941-a4d0a30f86f0"]},{"id":"summary","text":"The Federal Register published notice 2024-21941, attributed to FDA and its parent HHS department, on 2024-09-25. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DAYBUE,” and PeptideScanner's exact reviewed identity mapping connects the document to Trofinetide.","sourceIds":["federal-register-2024-21941-a4d0a30f86f0"]},{"id":"paragraph-1","text":"The Federal Register published notice 2024-21941, attributed to FDA and its parent HHS department, on 2024-09-25. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DAYBUE,” and PeptideScanner's exact reviewed identity mapping connects the document to Trofinetide.","sourceIds":["federal-register-2024-21941-a4d0a30f86f0"]},{"id":"paragraph-2","text":"This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use.","sourceIds":["federal-register-2024-21941-a4d0a30f86f0"]}],"sources":[{"id":"federal-register-2024-21941-a4d0a30f86f0","name":"Federal Register via GovInfo","sourceClass":"A","title":"Federal Register notice 2024-21941 · published 2024-09-25 · Determination of Regulatory Review Period for Purposes of Patent Extension; DAYBUE","url":"https://www.govinfo.gov/content/pkg/FR-2024-09-25/pdf/2024-21941.pdf"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"7cd79a5ab586683560129957d77f2020aa3bc5d7c291e04e1659ba66a9f4f64c","tierARecordSha256":"a4d0a30f86f07f1a6de1f8b294c57711cc2db89a07bcfb9c8a26425ed89fd5f2"},"integrity":{"algorithm":"sha256","contentSha256":"4a1f2eb672a9a00f6f9e7afb8f83c90f810239a2abaa079f3e71213c828111d7"}},"pubmed-pmid-37279541-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-37279541-trofinetide:v1","objectPathId":"pubmed-pmid-37279541-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-37279541-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-37279541-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-37279541-trofinetide-v1"},"story":{"slug":"pubmed-pmid-37279541-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2023-10-24","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Trofinetide.","sourceIds":["pubmed-observation-pmid-37279541-2023-10-24-b6a89c9fbdd6"]},{"id":"summary","text":"PubMed lists PMID 37279541 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2023-07-21 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-37279541-2023-10-24-b6a89c9fbdd6"]},{"id":"paragraph-1","text":"PubMed lists PMID 37279541 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2023-07-21 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-37279541-2023-10-24-b6a89c9fbdd6"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-37279541-2023-10-24-b6a89c9fbdd6"]}],"sources":[{"id":"pubmed-observation-pmid-37279541-2023-10-24-b6a89c9fbdd6","name":"PubMed","sourceClass":"A","title":"Trofinetide. · retained source version 1:2023-10-24:current:b6a89c9fbdd66fbaac6f144bad6de64b904f9dff1f9c4dde63f9c6b89adea4af","url":"https://pubmed.ncbi.nlm.nih.gov/37279541/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"1de432f482896b6b7a35ef58c8236a1306f9707ea6813d3020b830cf9d04ad00","tierARecordSha256":"b83daeaeb451d078efd5c91bfeda4310b9ce036a807e058671ccfeedcdea947b"},"integrity":{"algorithm":"sha256","contentSha256":"bc51c9d4d5cba7516478ab49af8f7f94fd99dd3c1d4783061accfa457399e5ee"}},"pubmed-pmid-37291210-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-37291210-trofinetide:v1","objectPathId":"pubmed-pmid-37291210-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-37291210-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-37291210-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-37291210-trofinetide-v1"},"story":{"slug":"pubmed-pmid-37291210-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2025-12-01","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study.","sourceIds":["pubmed-observation-pmid-37291210-2025-12-01-1e6945877def"]},{"id":"summary","text":"PubMed lists PMID 37291210 in Nature medicine as Clinical Trial, Phase III, Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-06-08 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-37291210-2025-12-01-1e6945877def"]},{"id":"paragraph-1","text":"PubMed lists PMID 37291210 in Nature medicine as Clinical Trial, Phase III, Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-06-08 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-37291210-2025-12-01-1e6945877def"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-37291210-2025-12-01-1e6945877def"]}],"sources":[{"id":"pubmed-observation-pmid-37291210-2025-12-01-1e6945877def","name":"PubMed","sourceClass":"A","title":"Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. · retained source version 1:2025-12-01:current:1e6945877def3b5d9b1b1c0b6a13daad9cb9b545e88cbe3f9b62652234937d62","url":"https://pubmed.ncbi.nlm.nih.gov/37291210/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"bf59a259832ff95c32806fc6a68e8049d5f9e18cf6866aab9f4c6b70475680c7","tierARecordSha256":"a9493a54485220e1dd05daa4ba8c18a41642bc25eaf951e11d250c85748f02d6"},"integrity":{"algorithm":"sha256","contentSha256":"0e19eab293b315007e850c0ef29bf1b3fbec474d79f51459328e2d33ddd7d48f"}},"pubmed-pmid-37460385-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-37460385-trofinetide:v1","objectPathId":"pubmed-pmid-37460385-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-37460385-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-37460385-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-37460385-trofinetide-v1"},"story":{"slug":"pubmed-pmid-37460385-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2024-10-03","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Trofinetide: a pioneering treatment for Rett syndrome.","sourceIds":["pubmed-observation-pmid-37460385-2024-10-03-1fbe8c7a869b"]},{"id":"summary","text":"PubMed lists PMID 37460385 in Trends in pharmacological sciences as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-07-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-37460385-2024-10-03-1fbe8c7a869b"]},{"id":"paragraph-1","text":"PubMed lists PMID 37460385 in Trends in pharmacological sciences as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-07-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-37460385-2024-10-03-1fbe8c7a869b"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-37460385-2024-10-03-1fbe8c7a869b"]}],"sources":[{"id":"pubmed-observation-pmid-37460385-2024-10-03-1fbe8c7a869b","name":"PubMed","sourceClass":"A","title":"Trofinetide: a pioneering treatment for Rett syndrome. · retained source version 1:2024-10-03:current:1fbe8c7a869b6669d32e22ccf5af1fc270c4cc578c503ef733dd193dff388802","url":"https://pubmed.ncbi.nlm.nih.gov/37460385/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"c7aaa8bf39dcd97454919b3c45e7e79a02e22c29c018d4d5b3d1cc823d7e3418","tierARecordSha256":"ae586c9b532ce8e7469a4084f71bfc5028708532f7a252bb9cccd1e96d11fa20"},"integrity":{"algorithm":"sha256","contentSha256":"8bb76ad9f2bee2636d186583877ef1b637b7bea2594590b1c2bfc4488d94fa7a"}},"pubmed-pmid-38035006-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-38035006-trofinetide:v1","objectPathId":"pubmed-pmid-38035006-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-38035006-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-38035006-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-38035006-trofinetide-v1"},"story":{"slug":"pubmed-pmid-38035006-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2023-12-02","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Trofinetide-a new chapter in rett syndrome's treatment.","sourceIds":["pubmed-observation-pmid-38035006-2023-12-02-a2366d99985d"]},{"id":"summary","text":"PubMed lists PMID 38035006 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2023-11-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-38035006-2023-12-02-a2366d99985d"]},{"id":"paragraph-1","text":"PubMed lists PMID 38035006 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2023-11-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-38035006-2023-12-02-a2366d99985d"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-38035006-2023-12-02-a2366d99985d"]}],"sources":[{"id":"pubmed-observation-pmid-38035006-2023-12-02-a2366d99985d","name":"PubMed","sourceClass":"A","title":"Trofinetide-a new chapter in rett syndrome's treatment. · retained source version 1:2023-12-02:current:a2366d99985d4039de7b1916f65f6e36c742dca533ba6503f6d1fe0a5d687c3d","url":"https://pubmed.ncbi.nlm.nih.gov/38035006/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"d71e6a8d75e14b018a0289a6010b6a3691d4b4c635c3b6a0ae7c8b43ed430a1c","tierARecordSha256":"1ade90d99b874aa6ad0fbbdbbd7cd565096ded1fa7dd4d49016ffb66c91654b8"},"integrity":{"algorithm":"sha256","contentSha256":"f1d1797b4d7199e8d3e13cc897e03df67224fc80bb2726d718c562930a6232c9"}},"pubmed-pmid-38318312-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-38318312-trofinetide:v1","objectPathId":"pubmed-pmid-38318312-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-38318312-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-38318312-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-38318312-trofinetide-v1"},"story":{"slug":"pubmed-pmid-38318312-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2024-10-31","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Development of trofinetide for the treatment of Rett syndrome: from bench to bedside.","sourceIds":["pubmed-observation-pmid-38318312-2024-10-31-1cd0d41cdd0d"]},{"id":"summary","text":"PubMed lists PMID 38318312 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2024-01-22 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-38318312-2024-10-31-1cd0d41cdd0d"]},{"id":"paragraph-1","text":"PubMed lists PMID 38318312 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2024-01-22 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-38318312-2024-10-31-1cd0d41cdd0d"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-38318312-2024-10-31-1cd0d41cdd0d"]}],"sources":[{"id":"pubmed-observation-pmid-38318312-2024-10-31-1cd0d41cdd0d","name":"PubMed","sourceClass":"A","title":"Development of trofinetide for the treatment of Rett syndrome: from bench to bedside. · retained source version 1:2024-10-31:current:1cd0d41cdd0d0c511086c0a7d2c41b13ee59c2ee1fe622398a410205ec38dbec","url":"https://pubmed.ncbi.nlm.nih.gov/38318312/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"091a294058024be532835fc9fd0cfbe57b91f127e77b278c6bf321baf932acf6","tierARecordSha256":"e6ea4f518431f6c27a82940d38ebf6ce3f144a1426a177ebf368be64ca231c51"},"integrity":{"algorithm":"sha256","contentSha256":"41775d5e588d22429b8589fd86a128119f3c6801d2b463b81814ae76343e64fa"}},"pubmed-pmid-38378975-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-38378975-trofinetide:v1","objectPathId":"pubmed-pmid-38378975-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-38378975-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-38378975-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-38378975-trofinetide-v1"},"story":{"slug":"pubmed-pmid-38378975-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2026-01-16","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives.","sourceIds":["pubmed-observation-pmid-38378975-2026-01-16-b7132ceeb4f8"]},{"id":"summary","text":"PubMed lists PMID 38378975 in Advances in therapy as Clinical Trial, Phase III, Journal Article, with publication-date metadata of 2024-02-20 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-38378975-2026-01-16-b7132ceeb4f8"]},{"id":"paragraph-1","text":"PubMed lists PMID 38378975 in Advances in therapy as Clinical Trial, Phase III, Journal Article, with publication-date metadata of 2024-02-20 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-38378975-2026-01-16-b7132ceeb4f8"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-38378975-2026-01-16-b7132ceeb4f8"]}],"sources":[{"id":"pubmed-observation-pmid-38378975-2026-01-16-b7132ceeb4f8","name":"PubMed","sourceClass":"A","title":"Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives. · retained source version 1:2026-01-16:current:b7132ceeb4f824db8522bf023e91e93e95685165105fe95833c921d4f052961b","url":"https://pubmed.ncbi.nlm.nih.gov/38378975/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"43ba9e8346dee11f51b4222b496e1f082c79fdae0fab77a0b32dae80e86f3090","tierARecordSha256":"b02010273800936f3c054c5bf6e1c3f4963c981d05c1fd5fa6b2e86ac1d7dcd7"},"integrity":{"algorithm":"sha256","contentSha256":"34c11ed1cec2c7aa7231784bc0dcdbf7321b84ebf21fafbab16a4ba34d6cb8a2"}},"pubmed-pmid-38555801-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-38555801-trofinetide:v1","objectPathId":"pubmed-pmid-38555801-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-38555801-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-38555801-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-38555801-trofinetide-v1"},"story":{"slug":"pubmed-pmid-38555801-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2024-05-11","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Look at DAYBUE™ (Trofinetide) as first ever drug for treatment of Rett Syndrome.","sourceIds":["pubmed-observation-pmid-38555801-2024-05-11-301b0cd6cf5b"]},{"id":"summary","text":"PubMed lists PMID 38555801 in Asian journal of psychiatry as Letter, with publication-date metadata of 2024-03-19 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-38555801-2024-05-11-301b0cd6cf5b"]},{"id":"paragraph-1","text":"PubMed lists PMID 38555801 in Asian journal of psychiatry as Letter, with publication-date metadata of 2024-03-19 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-38555801-2024-05-11-301b0cd6cf5b"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-38555801-2024-05-11-301b0cd6cf5b"]}],"sources":[{"id":"pubmed-observation-pmid-38555801-2024-05-11-301b0cd6cf5b","name":"PubMed","sourceClass":"A","title":"Look at DAYBUE™ (Trofinetide) as first ever drug for treatment of Rett Syndrome. · retained source version 1:2024-05-11:current:301b0cd6cf5b8ede0bd10b9835c293184176916272c546694a651d3ad79040ab","url":"https://pubmed.ncbi.nlm.nih.gov/38555801/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"637842d6bb066030a0b7a81d37fcad3693eeed29bca29cda3d50deeefbd58348","tierARecordSha256":"795cefc9c51cea088df023507b5a4967f78494443d6be770ca100a10227ddce1"},"integrity":{"algorithm":"sha256","contentSha256":"1bcfaca1a1d8eb184916bde309eae216ddaa7644b565dc5dbc55c4bcae3086a9"}},"pubmed-pmid-38869952-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-38869952-trofinetide:v1","objectPathId":"pubmed-pmid-38869952-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-38869952-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-38869952-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-38869952-trofinetide-v1"},"story":{"slug":"pubmed-pmid-38869952-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2024-07-16","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Recommendations for the management of gastrointestinal comorbidities with or without trofinetide use in Rett syndrome.","sourceIds":["pubmed-observation-pmid-38869952-2024-07-16-cee7b36fb0bb"]},{"id":"summary","text":"PubMed lists PMID 38869952 in Expert review of gastroenterology & hepatology as Journal Article, Review, with publication-date metadata of 2024-06-18 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-38869952-2024-07-16-cee7b36fb0bb"]},{"id":"paragraph-1","text":"PubMed lists PMID 38869952 in Expert review of gastroenterology & hepatology as Journal Article, Review, with publication-date metadata of 2024-06-18 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-38869952-2024-07-16-cee7b36fb0bb"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-38869952-2024-07-16-cee7b36fb0bb"]}],"sources":[{"id":"pubmed-observation-pmid-38869952-2024-07-16-cee7b36fb0bb","name":"PubMed","sourceClass":"A","title":"Recommendations for the management of gastrointestinal comorbidities with or without trofinetide use in Rett syndrome. · retained source version 1:2024-07-16:current:cee7b36fb0bb7148b9beb111edc08009a5f043439c354a784952ee52e0b4d5b8","url":"https://pubmed.ncbi.nlm.nih.gov/38869952/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"119040d07bf223cabd95d8313c0dbbb18dcf01c7a6d7c5c7592f6e6128c48a26","tierARecordSha256":"49c7e79db4127580b61f2540fb040dea1b01e25b6f9ef136963b8791824dfc3d"},"integrity":{"algorithm":"sha256","contentSha256":"ce2abcbc7b5c19cf25ad3a163b0774b703b13b7d213e61ecec724561c28d42ad"}},"pubmed-pmid-38981105-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-38981105-trofinetide:v1","objectPathId":"pubmed-pmid-38981105-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-38981105-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-38981105-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-38981105-trofinetide-v1"},"story":{"slug":"pubmed-pmid-38981105-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2024-07-15","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Trofinetide (Daybue) for Rett syndrome.","sourceIds":["pubmed-observation-pmid-38981105-2024-07-15-46a3d1c0c2e8"]},{"id":"summary","text":"PubMed lists PMID 38981105 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2024-07-08 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-38981105-2024-07-15-46a3d1c0c2e8"]},{"id":"paragraph-1","text":"PubMed lists PMID 38981105 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2024-07-08 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-38981105-2024-07-15-46a3d1c0c2e8"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-38981105-2024-07-15-46a3d1c0c2e8"]}],"sources":[{"id":"pubmed-observation-pmid-38981105-2024-07-15-46a3d1c0c2e8","name":"PubMed","sourceClass":"A","title":"Trofinetide (Daybue) for Rett syndrome. · retained source version 1:2024-07-15:current:46a3d1c0c2e8d6ae19f1e0cc145ee7744994f9be9c706196b4db399a15d5a6b7","url":"https://pubmed.ncbi.nlm.nih.gov/38981105/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"b2381ba8c7cc01e0af335f7cda56967663656ee1b9e8d0c61c725958a65208b7","tierARecordSha256":"89f465f9b46fdb3b889317325d00fc40b360014c8cdfe5e06090be9494007081"},"integrity":{"algorithm":"sha256","contentSha256":"f8f5b81fb1538cef789500a523811af4e35f1fea8bdf85970e3fd26b214895d2"}},"pubmed-pmid-39395401-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-39395401-trofinetide:v1","objectPathId":"pubmed-pmid-39395401-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-39395401-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-39395401-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-39395401-trofinetide-v1"},"story":{"slug":"pubmed-pmid-39395401-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2026-06-04","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Trofinetide treatment for Rett syndrome: Lessons to learn.","sourceIds":["pubmed-observation-pmid-39395401-2026-06-04-803b92913ad9"]},{"id":"summary","text":"PubMed lists PMID 39395401 in Med (New York, N.Y.) as Journal Article, Comment, with publication-date metadata of 2024-10-11 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-39395401-2026-06-04-803b92913ad9"]},{"id":"paragraph-1","text":"PubMed lists PMID 39395401 in Med (New York, N.Y.) as Journal Article, Comment, with publication-date metadata of 2024-10-11 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-39395401-2026-06-04-803b92913ad9"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-39395401-2026-06-04-803b92913ad9"]}],"sources":[{"id":"pubmed-observation-pmid-39395401-2026-06-04-803b92913ad9","name":"PubMed","sourceClass":"A","title":"Trofinetide treatment for Rett syndrome: Lessons to learn. · retained source version 1:2026-06-04:current:803b92913ad9bc5c426197cded4a94d759a4ad8c00de01eed477354776164b93","url":"https://pubmed.ncbi.nlm.nih.gov/39395401/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"2c32792de4bbcd592450cb367779582fb54232103064dd0043a53c88008c452b","tierARecordSha256":"0562a54bc6616cbb127518ac59c887a09cd3682b367c5acd1f3451768dbe0158"},"integrity":{"algorithm":"sha256","contentSha256":"cf6026c0f2953bc5fab2d827596f6962128d31f1f21785873f50533f0a434615"}},"pubmed-pmid-39692837-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-39692837-trofinetide:v1","objectPathId":"pubmed-pmid-39692837-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-39692837-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-39692837-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-39692837-trofinetide-v1"},"story":{"slug":"pubmed-pmid-39692837-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2026-08-17","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2-4 Years with Rett Syndrome.","sourceIds":["pubmed-observation-pmid-39692837-2026-08-17-396ace5b868f"]},{"id":"summary","text":"PubMed lists PMID 39692837 in Advances in therapy as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-12-18 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-39692837-2026-08-17-396ace5b868f"]},{"id":"paragraph-1","text":"PubMed lists PMID 39692837 in Advances in therapy as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-12-18 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-39692837-2026-08-17-396ace5b868f"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-39692837-2026-08-17-396ace5b868f"]}],"sources":[{"id":"pubmed-observation-pmid-39692837-2026-08-17-396ace5b868f","name":"PubMed","sourceClass":"A","title":"Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2-4 Years with Rett Syndrome. · retained source version 1:2026-08-17:current:396ace5b868f7f3724f4f2c5943205eea5dcd4908af111273cb21c140e0a1dd3","url":"https://pubmed.ncbi.nlm.nih.gov/39692837/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"00ce6b292abd633a7a3a74dd9fb36b37c3674e32e0b7cb3395ed7426f72a2c0e","tierARecordSha256":"bac7433d0d7add6c53a337fa3b49542c9f57a2c1f1990014092e3efdcdc9cdbf"},"integrity":{"algorithm":"sha256","contentSha256":"f779825aa52d1da68bd9f85a00f3041603d84319cc9b8de014c5f95e51dd4dc8"}},"pubmed-pmid-39824747-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-39824747-trofinetide:v1","objectPathId":"pubmed-pmid-39824747-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-39824747-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-39824747-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-39824747-trofinetide-v1"},"story":{"slug":"pubmed-pmid-39824747-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2025-05-22","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical Trials.","sourceIds":["pubmed-observation-pmid-39824747-2025-05-22-cc8b040fbecc"]},{"id":"summary","text":"PubMed lists PMID 39824747 in Clinical therapeutics as Journal Article, with publication-date metadata of 2025-01-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-39824747-2025-05-22-cc8b040fbecc"]},{"id":"paragraph-1","text":"PubMed lists PMID 39824747 in Clinical therapeutics as Journal Article, with publication-date metadata of 2025-01-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-39824747-2025-05-22-cc8b040fbecc"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-39824747-2025-05-22-cc8b040fbecc"]}],"sources":[{"id":"pubmed-observation-pmid-39824747-2025-05-22-cc8b040fbecc","name":"PubMed","sourceClass":"A","title":"Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical Trials. · retained source version 1:2025-05-22:current:cc8b040fbeccad842cc682fce778d73eeaf82176deb3eb5898dc1132ac7c4ca8","url":"https://pubmed.ncbi.nlm.nih.gov/39824747/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"db12eb93c424cfc3f86c4a27f8c0d86378cc09e5af994fdd43e6f6897dca55dc","tierARecordSha256":"555b93d3b2d60613a92397a7152b87427e87cb67851680d6433cebf6c36d13cb"},"integrity":{"algorithm":"sha256","contentSha256":"b238ce235071f5236b4ecb4e4e34ef9958ef1bdbefc946d98c5f62727f286868"}},"pubmed-pmid-41850142-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-41850142-trofinetide:v1","objectPathId":"pubmed-pmid-41850142-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-41850142-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-41850142-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-41850142-trofinetide-v1"},"story":{"slug":"pubmed-pmid-41850142-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2026-07-11","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Design, synthesis and evaluation of trofinetide prodrug based on diketopiperazine strategy.","sourceIds":["pubmed-observation-pmid-41850142-2026-07-11-244df2acb68c"]},{"id":"summary","text":"PubMed lists PMID 41850142 in Bioorganic & medicinal chemistry as Journal Article, with publication-date metadata of 2026-03-14 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-41850142-2026-07-11-244df2acb68c"]},{"id":"paragraph-1","text":"PubMed lists PMID 41850142 in Bioorganic & medicinal chemistry as Journal Article, with publication-date metadata of 2026-03-14 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-41850142-2026-07-11-244df2acb68c"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-41850142-2026-07-11-244df2acb68c"]}],"sources":[{"id":"pubmed-observation-pmid-41850142-2026-07-11-244df2acb68c","name":"PubMed","sourceClass":"A","title":"Design, synthesis and evaluation of trofinetide prodrug based on diketopiperazine strategy. · retained source version 1:2026-07-11:current:244df2acb68c91d9b81d5b2b8ca918a7e51c006a6a84b9da4b90d2f1d9743e76","url":"https://pubmed.ncbi.nlm.nih.gov/41850142/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"425ecec8b65fd93275423db3ccbe573a3442eb6be95ebcad0af98aaf2781cb4f","tierARecordSha256":"3f861da398e3e9f02644cd0fa09d3b95a66f99e065ff3b020b17d2c56a436189"},"integrity":{"algorithm":"sha256","contentSha256":"4392fd65e7cea10e537b8272ae34193a6321bd48442443089ad9abe898e7f9b8"}},"pubmed-pmid-42083929-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-42083929-trofinetide:v1","objectPathId":"pubmed-pmid-42083929-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-42083929-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42083929-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-42083929-trofinetide-v1"},"story":{"slug":"pubmed-pmid-42083929-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2026-07-16","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Hydrophobic Tag-Assisted Scalable Synthesis of Trofinetide and Its GPE Analogues.","sourceIds":["pubmed-observation-pmid-42083929-2026-07-16-9105d1304fca"]},{"id":"summary","text":"PubMed lists PMID 42083929 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, with publication-date metadata of 2026 (year precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42083929-2026-07-16-9105d1304fca"]},{"id":"paragraph-1","text":"PubMed lists PMID 42083929 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, with publication-date metadata of 2026 (year precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42083929-2026-07-16-9105d1304fca"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-42083929-2026-07-16-9105d1304fca"]}],"sources":[{"id":"pubmed-observation-pmid-42083929-2026-07-16-9105d1304fca","name":"PubMed","sourceClass":"A","title":"Hydrophobic Tag-Assisted Scalable Synthesis of Trofinetide and Its GPE Analogues. · retained source version 1:2026-07-16:current:9105d1304fca542e3ee2043711fbee374ad7e1a2b2174df6d071482cebd10a8c","url":"https://pubmed.ncbi.nlm.nih.gov/42083929/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"403201687c0be6460a07cabe19d83ed074565580226b9243c102b24fbabb2dbe","tierARecordSha256":"805142b05f6f0f08f8153f93a30a2b28022f9279780bb108b272d6289ca6d2b4"},"integrity":{"algorithm":"sha256","contentSha256":"ea6620c35aadb8722e0de5628baba5e92715c01646d50fadd001ed14e4d924f5"}},"pubmed-pmid-42287113-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-42287113-trofinetide:v1","objectPathId":"pubmed-pmid-42287113-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-42287113-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42287113-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-42287113-trofinetide-v1"},"story":{"slug":"pubmed-pmid-42287113-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2026-06-13","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Rett syndrome and real-world treatment patterns of trofinetide in the United States.","sourceIds":["pubmed-observation-pmid-42287113-2026-06-13-3e1fd975fc09"]},{"id":"summary","text":"PubMed lists PMID 42287113 in Journal of medical economics as Journal Article, with publication-date metadata of 2026-06-13 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42287113-2026-06-13-3e1fd975fc09"]},{"id":"paragraph-1","text":"PubMed lists PMID 42287113 in Journal of medical economics as Journal Article, with publication-date metadata of 2026-06-13 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42287113-2026-06-13-3e1fd975fc09"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-42287113-2026-06-13-3e1fd975fc09"]}],"sources":[{"id":"pubmed-observation-pmid-42287113-2026-06-13-3e1fd975fc09","name":"PubMed","sourceClass":"A","title":"Rett syndrome and real-world treatment patterns of trofinetide in the United States. · retained source version 1:2026-06-13:current:3e1fd975fc09cebfd514d7e54518476584fd4ce39bf183b2887c47b93cb2defd","url":"https://pubmed.ncbi.nlm.nih.gov/42287113/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"b7d4e5a56f9d9553c3fbfcc76d6a03a0c9741f988f68d6648a523b3f451a689e","tierARecordSha256":"51583a115e7476391e1187a848989692e0fe9a9cc6e02f65425021f17f960d5e"},"integrity":{"algorithm":"sha256","contentSha256":"64cf48a769e8c6853ca0c9b2f2f9e2bac9b3157ed2b2102a90a4377eccd87cb6"}},"pubmed-pmid-42294489-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-42294489-trofinetide:v1","objectPathId":"pubmed-pmid-42294489-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-42294489-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42294489-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-42294489-trofinetide-v1"},"story":{"slug":"pubmed-pmid-42294489-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2026-09-26","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Real-World Treatment Landscape of Individuals with Rett Syndrome Treated and Untreated with Trofinetide in the United States.","sourceIds":["pubmed-observation-pmid-42294489-2026-09-26-2377f0792967"]},{"id":"summary","text":"PubMed lists PMID 42294489 in Journal of health economics and outcomes research as Journal Article, with publication-date metadata of 2026-06-11 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42294489-2026-09-26-2377f0792967"]},{"id":"paragraph-1","text":"PubMed lists PMID 42294489 in Journal of health economics and outcomes research as Journal Article, with publication-date metadata of 2026-06-11 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42294489-2026-09-26-2377f0792967"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-42294489-2026-09-26-2377f0792967"]}],"sources":[{"id":"pubmed-observation-pmid-42294489-2026-09-26-2377f0792967","name":"PubMed","sourceClass":"A","title":"Real-World Treatment Landscape of Individuals with Rett Syndrome Treated and Untreated with Trofinetide in the United States. · retained source version 1:2026-09-26:current:2377f0792967d0b3e7d4a325ae00a1a72c704fd9628695cf1729a7a2d29c3b8a","url":"https://pubmed.ncbi.nlm.nih.gov/42294489/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"8a33a5142526b8cbb1007194a788d77491f7c221f870be0254e6e53fc4070740","tierARecordSha256":"31934c221caaa3f6a793ad23e29dd0f4de9afcc964b0af6d05830d6ff8bd3c1f"},"integrity":{"algorithm":"sha256","contentSha256":"8f4f85b2dd09c5237a2e5538b2b0d94dee85796f1de08c0a5471cceea08c3465"}},"pubmed-pmid-42377739-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-42377739-trofinetide:v1","objectPathId":"pubmed-pmid-42377739-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-42377739-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42377739-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-42377739-trofinetide-v1"},"story":{"slug":"pubmed-pmid-42377739-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2026-10-01","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Real-World Demographics, Clinical Characteristics, and Predictors of Persistence Among Males with Rett Syndrome Treated with Trofinetide.","sourceIds":["pubmed-observation-pmid-42377739-2026-10-01-f347d406e0c8"]},{"id":"summary","text":"PubMed lists PMID 42377739 in Advances in therapy as Journal Article, with publication-date metadata of 2026-06-30 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42377739-2026-10-01-f347d406e0c8"]},{"id":"paragraph-1","text":"PubMed lists PMID 42377739 in Advances in therapy as Journal Article, with publication-date metadata of 2026-06-30 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42377739-2026-10-01-f347d406e0c8"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-42377739-2026-10-01-f347d406e0c8"]}],"sources":[{"id":"pubmed-observation-pmid-42377739-2026-10-01-f347d406e0c8","name":"PubMed","sourceClass":"A","title":"Real-World Demographics, Clinical Characteristics, and Predictors of Persistence Among Males with Rett Syndrome Treated with Trofinetide. · retained source version 1:2026-10-01:current:f347d406e0c82aa7df48455f585f12b1ea9a1ea2be56e637fe93892c101d74ad","url":"https://pubmed.ncbi.nlm.nih.gov/42377739/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"28098b9e8c64615f81f96126fe265dbd99a26996b8ed3613726b85bb0758e67a","tierARecordSha256":"aa8d07e5b28dcd703e24fa19b6350ce85d73006b479fdad94abb552eda9a0f02"},"integrity":{"algorithm":"sha256","contentSha256":"c2bb095566ca4ac58c19dec50ca49bf4fda17baf622fa8ed53eb25777992f168"}},"pubmed-pmid-42530159-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-42530159-trofinetide:v1","objectPathId":"pubmed-pmid-42530159-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-42530159-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42530159-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-42530159-trofinetide-v1"},"story":{"slug":"pubmed-pmid-42530159-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2026-08-13","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Mapping Trofinetide Polypharmacology in Rett Syndrome: A Multi-Stage Computational Analysis.","sourceIds":["pubmed-observation-pmid-42530159-2026-08-13-567c9f9ae050"]},{"id":"summary","text":"PubMed lists PMID 42530159 in Journal of computational chemistry as Journal Article, with publication-date metadata of 2026-08-05 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42530159-2026-08-13-567c9f9ae050"]},{"id":"paragraph-1","text":"PubMed lists PMID 42530159 in Journal of computational chemistry as Journal Article, with publication-date metadata of 2026-08-05 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42530159-2026-08-13-567c9f9ae050"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-42530159-2026-08-13-567c9f9ae050"]}],"sources":[{"id":"pubmed-observation-pmid-42530159-2026-08-13-567c9f9ae050","name":"PubMed","sourceClass":"A","title":"Mapping Trofinetide Polypharmacology in Rett Syndrome: A Multi-Stage Computational Analysis. · retained source version 1:2026-08-13:current:567c9f9ae050e9c047e4883452890a26bf46124687c391a4570081a120925d54","url":"https://pubmed.ncbi.nlm.nih.gov/42530159/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"484706d98bf6cd2c2ffe36a7cb631cab53f522d97309c41e3d27e2f72d554959","tierARecordSha256":"0967964aae267a2927465514f5eb69622efa0c8ab90b16201eb1a115c82d36b6"},"integrity":{"algorithm":"sha256","contentSha256":"81d47cb02b91fd23c95433e94bb84cbda5b729c5827cf67afae17aa75685d3b9"}},"pubmed-pmid-42563928-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-42563928-trofinetide:v1","objectPathId":"pubmed-pmid-42563928-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-42563928-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42563928-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-42563928-trofinetide-v1"},"story":{"slug":"pubmed-pmid-42563928-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2026-08-13","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method.","sourceIds":["pubmed-observation-pmid-42563928-2026-08-13-18d90e7808b2"]},{"id":"summary","text":"PubMed lists PMID 42563928 in Annals of the Child Neurology Society as Journal Article, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42563928-2026-08-13-18d90e7808b2"]},{"id":"paragraph-1","text":"PubMed lists PMID 42563928 in Annals of the Child Neurology Society as Journal Article, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42563928-2026-08-13-18d90e7808b2"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-42563928-2026-08-13-18d90e7808b2"]}],"sources":[{"id":"pubmed-observation-pmid-42563928-2026-08-13-18d90e7808b2","name":"PubMed","sourceClass":"A","title":"Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method. · retained source version 1:2026-08-13:current:18d90e7808b23db224cba424569b72b48ed5468ba9e0ca41b2279bf59667e6c6","url":"https://pubmed.ncbi.nlm.nih.gov/42563928/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"0e0dc9e2746c376748d3cab41cda800a4773278628c73946a28ef9c9fd4beb64","tierARecordSha256":"83afc7ed605a58f9326d98080fdb9659e97c377fcd15de4c952f02bdde3ac10f"},"integrity":{"algorithm":"sha256","contentSha256":"bbb522545ff6ccb4d3a9d70011d4d668fb27c643e7fa34b8dd4dd13bb8a737bd"}},"pubmed-pmid-42577214-trofinetide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-42577214-trofinetide:v1","objectPathId":"pubmed-pmid-42577214-trofinetide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-42577214-trofinetide/","json":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42577214-trofinetide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/trofinetide.md#pubmed-pmid-42577214-trofinetide-v1"},"story":{"slug":"pubmed-pmid-42577214-trofinetide","version":1,"domain":"Literature metadata","dateInSource":"2026-08-28","sourceCheckedAt":"2026-11-15","publishedAt":"2026-11-15","peptideSlugs":["trofinetide"],"peptides":[{"slug":"trofinetide","url":"https://peptidescanner.com/peptides/trofinetide/"}]},"claims":[{"id":"headline","text":"Characteristics of adult individuals with Rett syndrome treated or untreated with trofinetide in the United States.","sourceIds":["pubmed-observation-pmid-42577214-2026-08-28-b6c0596b4403"]},{"id":"summary","text":"PubMed lists PMID 42577214 in Frontiers in neurology as Journal Article, with publication-date metadata of 2026-07-27 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42577214-2026-08-28-b6c0596b4403"]},{"id":"paragraph-1","text":"PubMed lists PMID 42577214 in Frontiers in neurology as Journal Article, with publication-date metadata of 2026-07-27 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42577214-2026-08-28-b6c0596b4403"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-42577214-2026-08-28-b6c0596b4403"]}],"sources":[{"id":"pubmed-observation-pmid-42577214-2026-08-28-b6c0596b4403","name":"PubMed","sourceClass":"A","title":"Characteristics of adult individuals with Rett syndrome treated or untreated with trofinetide in the United States. · retained source version 1:2026-08-28:current:b6c0596b44034a5adf82bc0fcfda58b5fc82f8ae6fdba6cf121cf5253fccca21","url":"https://pubmed.ncbi.nlm.nih.gov/42577214/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"d06d2648a1f5485178cdb063a6dfc6f2613a2718d448d773f489498f0edc6903","tierARecordSha256":"95505740f0821dba76faa96dd770c42f951ddc36c68ad8739e8c3d0c636a032a"},"integrity":{"algorithm":"sha256","contentSha256":"d3f805b1368fdf8e177f32dad3e152fd49c177614f96db092734045368f4d274"}}}}
